4.6 Article

A new Nav1.7 mutation in an erythromelalgia patient

Journal

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2013.01.079

Keywords

Inherited neuropathy; Channelopathy; Pain; Erythromelalgia; Sodium channel

Funding

  1. Medical Research Service and Rehabilitation Research Service, Dept. of Veterans Affairs
  2. National Multiple Sclerosis Society
  3. erythromelalgia Association
  4. National Program for New Century Excellent Talents in University [NCET-06-0015]
  5. National Natural Science Foundation [30400168]

Ask authors/readers for more resources

Gain-of-function missense mutations of SCN9A gene, which encodes voltage-gated sodium channel Na(v)1.7, alter channel's biophysical properties causing painful disorders which are refractory to pharmacotherapy in the vast majority of patients. Here we report a novel SCN9A mutation (ca.T3947C) in exon 20 in a 9 year old patient, not present in 200 ethnically-matched control alleles; the mutation substitutes the invariant valine 1316 residue within DIII/S5 by alanine (V1316A). Voltage-clamp studies show that Na(v)1.7 V1316A mutation hyperpolarizes activation (-9 mV), and enhances response to ramp stimuli (3-fold), changes that are predicted to cause hyperexcitability of DRG neurons. V1316A also hyperpolarizes steady-state slow-inactivation (-9.9 mV), which is predicted to attenuate the effect of this mutation on DRG neuron firing. These changes are consistent with previously characterized Erytheromelalgia associated mutations of Na(v)1.7. (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available